TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.260
+0.050 (4.13%)
At close: May 8, 2026, 4:00 PM EDT
1.300
+0.040 (3.17%)
After-hours: May 8, 2026, 7:45 PM EDT
TScan Therapeutics Employees
TScan Therapeutics had 142 employees as of December 31, 2025. The number of employees decreased by 53 or -27.18% compared to the previous year.
Employees
142
Change
-53
Growth
-27.18%
Revenue / Employee
$64,338
Profits / Employee
-$875,387
Market Cap
75.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 142 | -53 | -27.18% | 142 | 0 |
| Sep 30, 2025 | 148 | -51 | -25.63% | 146 | 2 |
| Jun 30, 2025 | 210 | 22 | 11.70% | 208 | 2 |
| Mar 31, 2025 | 201 | 34 | 20.36% | 200 | 1 |
| Dec 31, 2024 | 195 | 41 | 26.62% | 194 | 1 |
| Sep 30, 2024 | 199 | 44 | 28.39% | 188 | 11 |
| Jun 30, 2024 | 188 | 39 | 26.17% | 175 | 13 |
| Mar 31, 2024 | 167 | 29 | 21.01% | 161 | 6 |
| Dec 31, 2023 | 154 | 16 | 11.59% | 154 | 0 |
| Sep 30, 2023 | 155 | 24 | 18.32% | 145 | 10 |
| Jun 30, 2023 | 149 | 31 | 26.27% | 135 | 14 |
| Mar 31, 2023 | 138 | 33 | 31.43% | 136 | 2 |
| Dec 31, 2022 | 138 | 33 | 31.43% | 137 | 1 |
| Sep 30, 2022 | 131 | 36 | 37.89% | 127 | 4 |
| Jun 30, 2022 | 118 | 43 | 57.33% | 115 | 3 |
| Mar 31, 2022 | 105 | 44 | 72.13% | 104 | 1 |
| Dec 31, 2021 | 105 | 47 | 81.03% | 104 | 1 |
| Sep 30, 2021 | 95 | 37 | 63.79% | 90 | 5 |
| Jun 30, 2021 | 75 | - | - | 73 | 2 |
| Mar 31, 2021 | 61 | - | - | 60 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| XBiotech | 85 |
| Acrivon Therapeutics | 76 |
| Seres Therapeutics | 66 |
| PMV Pharmaceuticals | 54 |
| Pliant Therapeutics | 49 |
| Gain Therapeutics | 21 |
| Rallybio | 14 |
TCRX News
- 3 days ago - TScan Therapeutics reports Q1 EPS (22c), consensus (17c) - TheFly
- 4 days ago - TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 12 days ago - TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting - GlobeNewsWire
- 24 days ago - TScan Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 4 weeks ago - TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - TScan Therapeutics price target raised to $5 from $4 at Wedbush - TheFly
- 2 months ago - TScan Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - TScan Therapeutics reports Q4 EPS (18c), consensus (28c) - TheFly